Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study
Yıl: 2024 Cilt: 6 Sayı: 1 Sayfa Aralığı: 32 - 43 Metin Dili: İngilizce DOI: 10.36519/idcm.2024.287 İndeks Tarihi: 04-04-2024
Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study
Öz: Objective: Patients with COVID-19 accompanying cancer have been reported to have higher morbidity and mortality. In this study, we aimed to evaluate the high-dose high intravenous anakinra treatment response and outcome in patients with COVID-19-associated cytokine storm accompanying cancer. Methods: This retrospective observational study was carried out at a tertiary referral center between September 01, 2021, and February 01, 2022, in Turkey. The study population consisted of two groups: patients receiving high-dose intravenous anakinra and patients treated with standard care. Results: Data from 146 patients in the anakinra group and 114 patients in the control group were analyzed. Malignancy frequency was 11% (n=16) in the anakinra group and 7% (n=8) in the control group. In survival analysis, a significantly lower survival rate was observed in patients with malignancy than those without in the control group (log-rank: p=0.002) and patients with malignancy in the control group compared to the anakinra group (log-rank: p=0.013). However, it did not differ between patients with and without malignancy in the anakinra group (log-rank: p=0.9). Conclusion: In the control group, mortality was higher in patients with malignancy compared to those without malignancy, but not in the anakinra group. Also, mortality was higher in patients receiving SoC compared to anakinra. Intravenous high-dose anakinra treatment is safe and effective in patients with COVID-19 accompanying cancer.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1 Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; What we know so far. Front Immunol. 2020;11:1446. [CrossRef]
- 2 Kaur S, Bansal R, Kollimuttathuillam S, Gowda AM, Singh B, Mehta D, Maroules M. The looming storm: blood and cytokines in COVID-19. Blood Rev. 2021;46:100743. [CrossRef]
- 3 Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. [CrossRef]
- 4 Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. [CrossRef]
- 5 Malcova H, Strizova Z, Milota T, Striz I, Sediva A, Cebecauerova D, et al. IL-1 Inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives. Front Immunol. 2021;11:619257. [CrossRef]
- 6 Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2020;67(11):e28581. [CrossRef]
- 7 Bektaş M, Yüce S, Ay M, Uyar MH, Önder ME, Kılıç Mİ. Highdose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity scorematched study in a single center. Inflammopharmacology. 2023;31(2):787-97. [CrossRef]
- 8 Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. New York: National Institute of health (NIH). [cited October 28, 2023]. Available from: https://www.covid19treatmentguidelines.nih.gov/
- 9 Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020;2(12):e754- 63. [CrossRef]
- 10 Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-55. Erratum in: JAMA Intern Med. 2021;181(7):1021. [CrossRef]
- 11 Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP, Chung CW, Friedman HJ, Hines DW. Performance of the quick COVID-19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID-19 in a community hospital setting. Int J Infect Dis. 2021;102:571-6. [CrossRef]
- 12 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. Erratum in: JAMA Intern Med. 2020;180(7):1031. [CrossRef]
- 13 Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088-9. [CrossRef]
- 14 Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893-903. [CrossRef]
- 15 Bektaş M, Kılıç Mİ. Predictors of mortality in severe and critical COVID-19 patients receiving high dose intravenous anakinra. J Immunol Clin Microbiol. 2023;8(1):7-16. [CrossRef]
- 16 Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel). 2020;12(2):287. [CrossRef]
- 17 Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol. 2020;22:90-7. [CrossRef]
- 18 Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112-22. [CrossRef]
- 19 Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943-7. [CrossRef]
- 20 Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223-49. [CrossRef]
- 21 Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6(4):232- 41. [CrossRef]
- 22 Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-68. [CrossRef]
- 23 CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a ran- domised controlled trial. Lancet Respir Med. 2021;9(3):295-304. [CrossRef]
- 24 Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022;75(1):e1128- 36. [CrossRef]
- 25 Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545-55. [CrossRef]
- 26 Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021;19(1):98. [CrossRef]
- 27 Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-31. [CrossRef]
- 28 Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G, et al. ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. J Innate Immun. 2022;14(3):218-228. [CrossRef]
| APA | Cakmak R, BEKTAS M (2024). Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. , 32 - 43. 10.36519/idcm.2024.287 |
| Chicago | Cakmak Ramazan,BEKTAS MURAT Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. (2024): 32 - 43. 10.36519/idcm.2024.287 |
| MLA | Cakmak Ramazan,BEKTAS MURAT Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. , 2024, ss.32 - 43. 10.36519/idcm.2024.287 |
| AMA | Cakmak R,BEKTAS M Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. . 2024; 32 - 43. 10.36519/idcm.2024.287 |
| Vancouver | Cakmak R,BEKTAS M Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. . 2024; 32 - 43. 10.36519/idcm.2024.287 |
| IEEE | Cakmak R,BEKTAS M "Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study." , ss.32 - 43, 2024. 10.36519/idcm.2024.287 |
| ISNAD | Cakmak, Ramazan - BEKTAS, MURAT. "Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study". (2024), 32-43. https://doi.org/10.36519/idcm.2024.287 |
| APA | Cakmak R, BEKTAS M (2024). Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. Infectious diseases and clinical microbiology (Online), 6(1), 32 - 43. 10.36519/idcm.2024.287 |
| Chicago | Cakmak Ramazan,BEKTAS MURAT Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. Infectious diseases and clinical microbiology (Online) 6, no.1 (2024): 32 - 43. 10.36519/idcm.2024.287 |
| MLA | Cakmak Ramazan,BEKTAS MURAT Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. Infectious diseases and clinical microbiology (Online), vol.6, no.1, 2024, ss.32 - 43. 10.36519/idcm.2024.287 |
| AMA | Cakmak R,BEKTAS M Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. Infectious diseases and clinical microbiology (Online). 2024; 6(1): 32 - 43. 10.36519/idcm.2024.287 |
| Vancouver | Cakmak R,BEKTAS M Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study. Infectious diseases and clinical microbiology (Online). 2024; 6(1): 32 - 43. 10.36519/idcm.2024.287 |
| IEEE | Cakmak R,BEKTAS M "Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study." Infectious diseases and clinical microbiology (Online), 6, ss.32 - 43, 2024. 10.36519/idcm.2024.287 |
| ISNAD | Cakmak, Ramazan - BEKTAS, MURAT. "Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study". Infectious diseases and clinical microbiology (Online) 6/1 (2024), 32-43. https://doi.org/10.36519/idcm.2024.287 |
